Medico company Bang & Olufsen Medicom, which originates from Danish audio systems manufacturer Bang & Olufsen, has entered a three year collaboration agreement with one of the world's largest pharmaceutical companies, reports financial daily newspaper Børsen. The collaboration involves development of the next generation of inhaler platform, which can provide safe and easy inhalation of drugs for patients suffering from asthma and chronic obstructive pulmonary disease.
MD Henrik Kagenow told Børsen that he considers the agreement a milestone since it will result in a technological solution that will create great progress as well as a seal of approval of one of the company's patented products.
"Our customers, which comprise four of the world's top ten pharmaceutical companies, are not as hard hit by the crisis as others, since the industry is characterised by long-term thinking. But the crisis does however give cause for caution and alertness. We are also cautious in Medicom, but it is mostly cautiously optimistic," he said.
Kagenow highlighted that while others have had to cut the number of staff in recent months, Bang & Olufsen Medicom has taken on more people.
Bang & Olufsen Medicon designs, manufactures and co-markets intelligent patient compliance device solutions such as injection and inhalation devices. The company employs about 100 people of whom 40 are engineers.